Kornimate/medical-research-clean huggingface dataset:
high dose of vitamin c on mechanically ventilated septic patients in intensive care unit

Conditions: Ventilator Associated Pneumonia ( VAP); Sepsis

Summary: prospective, randomized clinical trial study will be carried out in intensive care unit in ain shams university hospitals on 40 forty septic patients admitted to icu and mechanically ventilated.

this study will be carried out in intensive care unit in ain shams university hospitals , cairo,egypt on 40 patients admitted to icu that are septic patients and mechanically ventilated which will be recruited into the study . after approval from ethical committee, an informed consent will be obtained from relatives of all patients. all data of patients will be confidential with secret codes and private file for each patient. each patient's relative will receive an explanation for the purpose of the study. the study design will be prospective , randomized clinical trial. methodology: all patients will be subjected to: 1. complete history taking. 2. full clinical examination 3. evaluation and monitoring of(pulse oximetry , ecg, nibp, temperature) 4. cbc , blood gas (for determination of (pao2/fio2), blood cultures,serum creatinine and total bilirubin were recorded daily for the first 7 days. 5. severity scores by calculating acute physiology and chronic health evaluation (apache ii)score

Eligibility criteria:
inclusion criteria: * male or female * age from age≥18 years * septic patient admitted to icu and mechanically ventilated diagnosed by sepsis criteria proposed by the american college of chest physicians/society of critical care medicine * expected to survive and remain in the icu for at least 96 hours after study entry exclusion criteria: * age\<18 years * pregnant females * patients with history of aspiration before intubation * respiratory distress syndrome * ischemic reperfusion injury * cancer as the cause of sirs or sepsis * chronic kidney diseases * ongoing shock * allergy from interventional drug on the study

Keywords: vitamin c sepsis intensive care unit mechanically ventilation vap
carglumic acid in methylmalonic acidemia and propionic acidemia

Conditions: Propionic Acidemia; Methylmalonic Acidemia

Summary: a phase iiib (three b), randomized multicentre comparative trial to evaluate the long term effectiveness \& safety of the use of carglumic acid (carbaglu®) in patients with propionic acidemia (pa) or methylmalonic acidemia (mma). carbaglu® clinical experience in organic acidemia (oa) is limited to a non-comparative retrospective collection of data from patients who had received carbaglu® for 1 to 15 days. there is no current evidence supporting the use of carglumic acid for the chronic management of patients with oa. the investigators are proposing a randomized multicentre prospective clinical trial to evaluate long-term effects of the use of carbaglu® (50mg/kg/day) combined with standard chronic therapy in patients with pa and mma compared to standard chronic therapy alone.


Eligibility criteria:
inclusion criteria: * male or female children of 15 years old or less * parent or legal guardian agree to participate and to sign the (institutional review board) irb approved informed consent form (assent forms will be waived due to the mental disability of those children) * not participating in any other clinical trial in the previous 30 days * pa or mma confirmed using the following criteria: * pa confirmed by the measurement of acylcarnitine profile, urine organic acid, measurement of propionyl co-a carboxylase in leukocytes or cultured fibroblasts or by dna molecular testing of pcca (propionyl coa carboxylase, alpha polypeptide) or pccb (propionyl coa carboxylase, beta polypeptide) gene * mma confirmed by the measurement of acylcarnitine profile, urine organic acid, measurement of methymalonyl co-a mutase in culture fibroblasts or dna molecular testing of mutgene. * expected survival of at least 6 months, for the purpose of this study survival expectance will be defined as patient not admitted to the pediatric intensive care unit (picu) due to hyperammonemia more than 2 times per year or asymptomatic patients diagnosed by newborn screening program or stable chronic patients who are followed up at outpatient clinic. exclusion criteria: * patients with other organic acidemia or any other cause of hyperammonemia * patient receiving other investigational therapy for pa or mma * past history of hypersensitivity or drug allergy to carbaglu® * patient with pa or mma and other inherited genetic conditions or congenital anomalies
prevention of transmission of hepatitis c virus (hcv) from hcv-viremic organ donor

Conditions: Hepatitis C; Hepatitis C Virus Infection, Response to Therapy of

Summary: this trial will be done in participants who undergo transplantation of heart, kidney or lung at university of california, san diego (ucsd) and receive a hepatitis c infected donor organ. in this trial, the plan is to start hepatitis c treatment just before transplant surgery and treat for a short one-week course to see if hepatitis c infection can be prevented in the transplant recipient. the plan is to perform this trial in 10 participants and if successful, the next step is to try to make it standard of care as prevention of infection is better than treating hepatitis c after discharge from transplant surgery (which is usually a 12 week standard treatment).


Eligibility criteria:
inclusion criteria: * adults aged 18 years or greater * participants actively listed for heart, lung and/or kidney transplant * participants have already consented to receive hcv-viremic organs as part of the institution's clinical practice protocol (involves education and informed consent), and are able to sign informed consent for this research study. exclusion criteria: * participants who have a prior history of hcv infection regardless of treatment status, pre-existing human immunodeficiency virus (hiv) or hepatitis b virus (hbv) infection * participants who are not able to sign informed consent for this research study * participants who have not agreed to accept hcv+ organs as part of the ucsd clinical practice protocol * participants who are listed for a liver transplant (either as a single organ or combined organ transplant).
palliative care intervention in improving quality of life, psychological distress, and communication in patients with solid tumors receiving treatment

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Summary: this pilot randomized clinical trial studies palliative care intervention in improving quality of life, psychological distress, and communication in patients with solid tumors receiving treatment on phase i trials. cancer patients experience many symptoms related to treatment and the cancer itself that can be distressing and impact quality of life. palliative care focuses on managing these symptoms and may help patients with solid tumors live more comfortably.

primary objectives: i. test the effects of a palliative care intervention (pci) on patients' quality of life (qol), psychological distress and satisfaction with communication, comparing the experimental versus control groups. ii. test the effects of a pci on patients' symptom intensity and symptom interference with daily activities, comparing the experimental versus control groups. iii. test the effects of a pci on patients' hospital and palliative care resource utilization and clinical trial retention rates, comparing the experimental versus control groups. iv. test the effects of the timing of pci initiation (early versus delayed) on patient outcomes, comparing the experimental versus control groups. v. describe patients' satisfaction with the pci. outline: patients are randomized to 1 of 2 arms. arm i: patients receive part i of the pci comprising quantitative surveys, comprehensive palliative care assessment by the research nurses, and goals of care discussions beginning prior to administration of the first dose of phase i treatment. patients then receive part ii of the pci comprising recommendations from the interdisciplinary team, patient educational sessions, and supportive care referrals following the first dose of phase i treatment and is completed within one month of the first treatment. arm ii: patients receive usual care until 12 weeks post-treatment initiation. patients then receive both part i and ii of the pci. after completion of study, patients are followed up for 5 years.

Eligibility criteria:
inclusion criteria: * patients diagnosed with solid tumors who are eligible for participation in phase i clinical trials of investigational cancer therapies * patients who have signed an informed consent for participation in phase i clinical trials * able to read or understand english-this is included because the intervention and study materials (including outcome measures) are only in english * ability to read and/or understand the study protocol requirements, and provide written informed consent exclusion criteria: * patients diagnosed with hematologic (as a population distinct from solid tumors and different trials) cancers.
nexium (esomeprazole) in symptom adapted therapy in gerd patients

Conditions: GERD

Summary: to compare the efficacy of three different long-term treatment strategies of reflux disease in primary care setting.


Eligibility criteria:
inclusion criteria: * subjects who seek medical advice in primary care for symptoms thought to be gerd related (gerd is a condition which develops when the reflux of stomach content causes troublesome symptoms and / or complications). exclusion criteria: * subjects with any clinical gerd treatment (ppi, h2-receptor antagonists) within the last 3 months prior to visit 1. * a history of severe esophagitis or known other complications, with alarm symptoms

Keywords: gastroesophageal reflux disease acid reflux
safety, tolerability, immunogenicity and cpg dosage finding study of novartis cpg adjuvanted flu vaccine

Conditions: Influenza Infection

Summary: to evaluate the safety and tolerability of the an adjuvanted influenza vaccine combined with cpg7909 at three different doses of cpg 7909 as a single intramuscular (im) administration in healthy adults. safety will be assessed by observation of symptoms, physical examination findings and laboratory safety testing.


Eligibility criteria:
inclusion criteria: * healthy subjects aged 18 to ≤40 years exclusion criteria: * any serious disease, hypersensitivity to egg or vaccine components, neurological symptoms or positive antibody test against dsdna, rf, ana or thyroid. * abnormal tsh from blood samples collected during the screening visit;

Keywords: adjuvanted influenza vaccine
exendin-9,39 and satiety after bariatric surgery

Conditions: Obesity

Summary: the overall aim of the application is to determine the contribution of the elevated incretin hormone concentrations seen after certain types of bariatric surgery to the regulation of food intake and satiety.

both sleeve gastrectomy (sg) and roux-en-y gastric bypass (rygb) increase glp-1 concentrations, although this is of lesser magnitude in sg compared to rygb. data suggests that endogenous glp-1 is at least partially responsible for reducing free-choice caloric intake after rygb, providing a mechanism underlying differences between procedures. inhibition of glp-1 action with exendin-9,39 after rygb accelerates gastric emptying. these observations suggest that factors other than anatomy regulate the upper gastrointestinal response to food ingestion. it is therefore reasonable to consider that the postprandial rise in glp-1 might affect feeding behavior after rygb, and to a lesser extent sg, where the increase in glp-1 is less marked.

Eligibility criteria:
inclusion criteria: * undergone either sleeve gastrectomy or roux-en-y gastric bypass surgery within prior 2 years * healthy, with no active systemic illness exclusion criteria: * pregnancy * functional or organic bowel symptoms * systemic illness * diabetes * bariatric surgery \> 2 years

Keywords: sleeve gastrectomy roux-en-y gastric bypass
deep brain stimulation (dbs) for obsessive compulsive disorder (ocd): improving targeting precision

Conditions: Obsessive-Compulsive Disorder

Summary: when comparing targeting precision between dbs in parkinsonian patients and ocd patients, an unexpected deviation from the planned targets was discovered in ocd patients (nuttin et al., 2013). the objective of this trial is to investigate whether the use of a micro-electrode assisted technique improves targeting precision in dbs at the bnst.


Eligibility criteria:
inclusion criteria: * diagnosis of ocd following the diagnostic and statistical manual of mental disorders-fourth edition (dsm-iv) criteria for ocd (300.3). * failure of documented trials of pharmacotherapy, following an appropriate treatment algorithm for ocd. * failure of documented trial of cognitive and behavioural therapy * duration of illness: min. 5 year * y-bocs (yale-brown obsessive compulsive scale) at least 30/40. * age: 20-65 year exclusion criteria: * dsm-iv diagnosis on axis 2 of severe personality disorder in cluster a or b, especially in the case of heightened risk for acting-out behavior. * dsm-iv diagnosis on axis 3 of organic brain pathology or significant abnormalities on mri. * present or past history of psychotic symptoms. * present substance abuse, or instable remission of substance abuses (i.e. no substance abuse during the last 12 months). * any disorder affecting cognitive functioning, other than motor tics and gilles de la tourette's syndrome * mental retardation. a minimum threshold of cognitive skills is needed for adequate reporting on questionnaires and evaluation, and for technical handling of the instruments in a later faze.

Keywords: deep brain stimulation ocd
multiple ascending dose study of bms-820132 in patients with type 2 diabetes

Conditions: Type 2 Diabetes

Summary: bms-820132 is an investigational new drug being developed by bms for treating type 2 diabetes. the purpose of this study is to test the safety/tolerability (potential side effects) of multiple doses of the investigational new drug, as well as the amount of study drug in the blood and its effects on blood sugar,in subjects with type 2 diabetes.

study classification: safety, pharmacokinetics/dynamics

Eligibility criteria:
inclusion criteria: * males and females of childbearing potential (willing to use an acceptable method of contraception), or females of non-childbearing potential (i.e., post-menopausal or surgically sterile). * diagnosis of type 2 diabetes treated with metformin monotherapy (at least 1500 mg/day for at least 6 months) on a stable regimen for at least 2 months. * body mass index (bmi) of 18.5 to 40 kg/m2. * fasting glucose in the range of 125-275 mg/dl. * hemoglobin a1c (hba1c) in the range of 7.0% -11.0%. * fasting c-peptide \> 1 ng/ml. exclusion criteria: * clinically significant deviation from normal in medical history, physical examination, electrocardiograms (ecgs), and clinical laboratory determinations, and any significant acute or chronic medical illness other than stable and well controlled hypertension, microalbuminuria, dyslipidemia, depression, or hypothyroidism. * history of diabetic ketoacidosis, hyperosmolar nonketotic syndrome, lactic acidosis, hypoglycemia (i.e., ≥ 1 self-reported episodes of hypoglycemia within the last 3 months or ≥ 2 self-reported episodes of hypoglycemia within the last 6 months), or hypoglycemia unawareness. * any major surgery within 4 weeks of study drug administration. * any gastrointestinal surgery that could impact upon the absorption of study drug. * smoking more than 10 cigarettes per day. * recent drug or alcohol abuse. * women who are pregnant or breastfeeding. * positive urine screen for drugs of abuse. * positive blood screen for hepatitis c antibody, hepatitis b surface antigen, or human immunodeficiency virus (hiv)-1, -2 antibody.
impact of isotretinoin in different doses on quality of life

Conditions: Acne Vulgaris

Summary: the cardiff acne disability index is a short five-item questionnaire derived from the longer acne disability index.it is designed for use in teenagers and young adults with acne. it is self explanatory and can be simply handed to the patient who is asked to complete it without the need for detailed explanation( .abdelrazik etal., 2021). .

lower doses of isotretinoin can be effective in terms of cost and decreasing systemic side effects. therefore, other regimens may be used instead of daily conventional dose as alternate, pulse and low doses of oral isotretinoin in acne vulgaris( agarwal et al., 2011). to study the impact of different protocols of systemic isotretinoin in acne treatment on quality of life among egyptian patients using cardiff acne disability index (cadi) and dermatology life quality index (dlqi)questionnaires. to assess validity and reliability of the translated arabic version of cadi. to compare the clinical efficacy and tolerability of different protocols of systemic isotretinoin in acne treatment.

Eligibility criteria:
inclusion criteria: patients with clinically diagnosed acne vulgaris older than 18 years of age - exclusion criteria: patients having personal or family history of hyperlipidemia. pregnancy and lactation. newly married female desiring to get pregnant or using temporary method of contraception. patients with a history suggestive of any psychic disturbance -
antibodies causing epilepsy syndromes: the aces study.

Conditions: Auto-immune Encephalitis; Epilepsy

Summary: the antibodies causing epilepsy syndromes (aces) study is a observational cohort study focusing on detection of auto-immune epilepsy in patients with epilepsy of unknown origin.

recently new treatable causes of epilepsy have been identified. these disorders are caused by a disruption of the balance in the brain caused by inflammation. this inflammatory reaction is caused by an autologous reaction of the immune system to specific brain proteins. the body produces antibodies to specific parts of the brain. these disorders can lead to epilepsy, memory dysfunction and psychiatric problems. recognition is necessary for good treatment. mostly anti-epileptic drugs are insufficient. these diseases can be treated with immune-modulating therapy. the aces study will focus on determining the frequencies of known antibodies and finding new, currently unknown, antibodies, causing epilepsy. therefore patients will be investigated with epilepsy of unknown origin. to find new antibodies sera of patients with epilepsy will be added to brain sections of rats and to cultivated neuronal cells to look for a reaction. if new antibodies will be detected clinical features will be mapped of the patients. also effects of antibodies on brain cells will be determined. discovery of new antibodies can provide new treatment options for these patients. also it will enable to discover more about the pathologic mechanisms of epilepsy.

Eligibility criteria:
inclusion criteria: * age of 18 and older. * status epilepticus or new onset seizures with signs of limbic encephalitis (clinical picture, mri (flair abnormalities), eeg abnormalities or csf findings (csf pleocytosis, increased igg index, oligoclonal bands), or: * patients with acquired chronic focal epilepsy with an unknown cause. exclusion criteria: * children * epilepsy with known cause

Keywords: antibodies auto-immune encephalitis epilepsy limbic encephalitis
effect of minimally processed animal protein on biomarkers for cognitive decline

Conditions: Healthy Lifestyle

Summary: minimally processed animal protein is a premier source of essential macro and micronutrients in the diet and is important, especially to older adults who are at increased risk of nutritional deficiency and age-related physiological changes. our central hypothesis is that adding lean animal protein within a healthy diet following macronutrient recommendations for americans will enhance nutrient adequacy and attenuate markers of cognitive decline. this is a retrospective study leveraging samples collected from the feeding trial nct05581953. pi for both studies are the same.


Eligibility criteria:
inclusion criteria: * generally, good health status based on one routine physical in the past 15 months, current health status * normal hba1c, weigh 110 lb or more * age 65 years or more, generally healthy, all races and both sexes * generally practicing a meat-based dietary pattern, do not have any special dietary requirements, and * willingness to comply with the study protocol, including on-site meal consumption and sample/data collection. exclusion criteria: * medication usage, probiotic, long-term antibiotic, and tobacco/drug/alcohol use * not on any special diet within 3 months of recruitment, and do not intend to lose weight * impaired kidney functions * active history of cancer, diabetes, heart, liver, and kidney diseases * major gastrointestinal disorders in the past 3 months * history of heart attacks or stroke * unable to meet in-person visit requirements for dining, picking up meals, and tests * any mental health condition affecting the ability to provide written informed consent * if they had not had a routine health checkup 12 months before recruitment. * if they were unwilling to abstain from taking nutritional supplements, alcohol, non-study foods, and beverages during the study period.
evaluating adult patient temperatures during lower spinal surgery

Conditions: Hypothermia

Summary: the purpose of this study is to evaluate patients' temperatures after using one of two ventilator circuits (breathing systems): the anapod™ heat and humidification system (anapod™ system) or the standard ventilator circuit with a heat-moisture exchanger (standard ventilator). the anapod™ system will provide additional heat and humidity to patients through their breathing tube while the standard ventilator will not. the investigators are doing this research study to find out if the ventilator circuit providing additional heat and humidity will keep patients warmer during surgery and after surgery.

patients were randomly assigned to either the treatment group or the control group prior to surgery. prior to induction, patients in the control group were given inspiratory gas at ambient air temperature (20-22 degrees celsius) and patients in the treatment group were given inspiratory gas at warmed temperatures (40-41 degrees celsius). all patients were induced with general anesthesia in the supine position and repositioned prone following endotracheal intubation and placement of an esophageal stethoscope with a temperature sensor, as per usual hospital practice. esophageal temperatures were recorded within 30 minutes of the baseline esophageal temperature and every 10 minutes thereafter for the first hour post-induction. all patients had a blanket and forced air warming applied to their lower extremities and upper back at 43 degrees celsius after draping. all patients had esophageal temperature measurements recorded every 30 minutes until the patient was repositioned supine. core temperatures were recorded four hours post-induction for those patients reaching that timeframe.

Eligibility criteria:
inclusion criteria: * elective spine surgery anticipated greater than three hours in duration * posterior approach * an operative site between lumbar one and sacral one * involving two or more levels with fusion and/or instrumentation and/or revisions * american society of anesthesiologists (asa) status of i-iii exclusion criteria: * patients with a tracheostomy * preoperative temperature \>38°c or \<36°c on the day of surgery * active infection or erythema to the back * white blood cell count greater than 10,500/microliter (mcl)
screening for fabry disease among young stroke patients in an israeli stroke clinic

Conditions: Fabry Disease in the Young Stroke

Summary: the purpose of this study is to determine the incidence of fabry disease in young stroke patients in an israeli stroke clinic.


Eligibility criteria:
inclusion criteria: diagnosis of stoke or tia time period within last 5 years - exclusion criteria: known diagnosis of stroke or index event due to trauma -